Effects of a low-level diode laser on oral keratinocytes, oral fibroblasts, endothelial cells and osteoblasts incubated with bisphosphonates: An in vitro study

Walter,Christian; Pabst,Andreas  Max; Ziebart,Thomas

doi:10.3892/br.2014.389

Effects of a low-level diode laser on oral keratinocytes, oral fibroblasts, endothelial cells and osteoblasts incubated with bisphosphonates: An in vitro study

Authors:
- Christian Walter
- Andreas Max Pabst
- Thomas Ziebart
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, University Medical Center, Johannes Gutenberg‑University Mainz, Germany
Published online on: November 17, 2014 https://doi.org/10.3892/br.2014.389
Pages: 14-18

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bisphosphonate‑associated osteonecrosis of the jaw may have multiple causes, including altered bone remodeling, angiogenesis inhibition and impact of bisphosphonate on the soft tissues. Successful treatment is difficult. As a positive effect of low‑level laser application on wound healing is well known, an in vitro study was designed to analyze the effect of low‑level laser (280 mW, 670 nm) treatment on keratinocytes, fibroblasts, endothelial cells and osteoblasts treated with clodronate, ibandronate, pamidronate or zoledronate. Pure irradiation had a positive effect on cell viability, whereas bisphosphonate treatment had a negative impact. Viability was significantly increased in cells treated with bisphosphonates and sequel irradiation. There was no effect when the bisphosphonate medium was irradiated. The revealed effect of laser stimulation on cell viability is not due to an inactivation of the bisphosphonates. These results may support the idea of low‑level laser therapy as a supportive therapy in patients receiving bisphosphonates to prevent and treat bisphosphonate‑associated osteonecrosis of the jaw.

View Figures

View References

1	Fleisch H: Bisphosphonates in osteoporosis. Eur Spine J. 12:S142–S146. 2003. View Article : Google Scholar
2	Diel IJ, Bergner R and Grötz KA: Adverse effects of bisphosphonates: current issues. J Support Oncol. 5:475–482. 2007.PubMed/NCBI
3	Walter C, Grötz KA, Kunkel M and Al-Nawas B: Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 15:197–202. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE and Mehrotra BAmerican Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 67:2–12. 2009. View Article : Google Scholar : PubMed/NCBI
5	Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J and Wagner W: Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 54:1066–1072. 2008. View Article : Google Scholar
6	Allen MR and Burr DB: The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 67 (Suppl 5):S61–S70. 2009. View Article : Google Scholar : PubMed/NCBI
7	Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC and Burr DB: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 15:613–620. 2000. View Article : Google Scholar : PubMed/NCBI
8	Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M and Clézardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62:6538–6544. 2002.PubMed/NCBI
9	Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B and Walter C: Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 15:105–111. 2011. View Article : Google Scholar : PubMed/NCBI
10	Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L and Raghavan S: Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 66:839–847. 2008. View Article : Google Scholar : PubMed/NCBI
11	Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H and Ziebart T: Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig. 14:35–41. 2010. View Article : Google Scholar : PubMed/NCBI
12	Stübinger S, Dissmann JP, Pinho NC, Saldamli B, Seitz O and Sader R: A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation. Lasers Surg Med. 41:26–30. 2009.PubMed/NCBI
13	Pereira AN, Eduardo Cde P, Matson E and Marques MM: Effect of low-power laser irradiation on cell growth and procollagen synthesis of cultured fibroblasts. Lasers Surg Med. 31:263–267. 2002. View Article : Google Scholar : PubMed/NCBI
14	Fujihara NA, Hiraki KR and Marques MM: Irradiation at 780 nm increases proliferation rate of osteoblasts independently of dexamethasone presence. Lasers Surg Med. 38:332–336. 2006. View Article : Google Scholar : PubMed/NCBI
15	Ninomiya T, Miyamoto Y, Ito T, Yamashita A, Wakita M and Nishisaka T: High-intensity pulsed laser irradiation accelerates bone formation in metaphyseal trabecular bone in rat femur. J Bone Miner Metab. 21:67–73. 2003. View Article : Google Scholar : PubMed/NCBI
16	Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L and Compston JECanadian Association of Oral and Maxillofacial Surgeons: Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 35:1391–1397. 2008.PubMed/NCBI
17	Grötz KA and Kreusch T: Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation. DZZ. 60:102006.(In German).
18	Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, Lahuerta JJ, Lluch A, Massuti B, Morote J, San Miguel JF and Solsona E: Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 12:E336–E340. 2007.
19	Marx RE, Cillo JE Jr..Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 65:2397–2410. 2007. View Article : Google Scholar : PubMed/NCBI
20	Bagan JV, Jimenez Y, Gomez D, Sirera R, Poveda R and Scully C: Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 44:1088–1089. 2008. View Article : Google Scholar
21	Pinheiro Al, Cavalcanti ET, Pinheiro TI, Alves MJ and Manzi CT: Low-level laser therapy in the management of disorders of the maxillofacial region. J Clin Laser Med Surg. 15:181–183. 1997.PubMed/NCBI
22	Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D'Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M and Vescovi P: Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed. 77:109–117. 2006.PubMed/NCBI
23	Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, Rocca JP and Nammour S: Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg. 26:37–46. 2008. View Article : Google Scholar